Molecular Weight: 586.54
Molecular Formula: C29H30O13
Canonical SMILES: O=C1C2=CO[C@H](O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)[C@@H](C=C)[C@@]2(OC(C4=C(O)C=C(O)C=C4C5=CC=CC(O)=C5)=O)CCO1
InChI: InChI=1S/C29H30O13/c1-2-16-17-6-7-38-26(36)19(17)12-39-28(16)42-29-25(24(35)23(34)21(11-30)40-29)41-27(37)22-18(9-15(32)10-20(22)33)13-4-3-5-14(31)8-13/h2-5,8-10,12,16-17,21,23-25,28-35H,1,6-7,11H2/t16-,17+,21-,23-,24+,25-,28+,29+/m1/s1
InChIKey: DBOVHQOUSDWAPQ-WTONXPSSSA-N
Boiling Point: 928.5±65.0 °C (Predicted)
Melting Point: 229-230 °C
Purity: 98%
Solubility: Soluble in DMSO.
Synonyms: sweroside-2'-(3'',5'',3'''-trihydroxydiphenyl)-2''-carboxylic acid ester; (4aS)-6α-[2-O-[(3,3',5-Trihydroxy-1,1'-biphenyl-2-yl)carbonyl]-β-D-glucopyranosyloxy]-5β-vinyl-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-1-one
DescriptionAmarogentin exhibits anti-oxidative, anti-tumour, and anti-diabetic activities. Amarogentin promotes apoptosis, arrests G2/M cell cycle and downregulates of PI3K/Akt/mTOR signalling pathways and displays immunomodulatory effects in human mast cells and keratinocytes. It inhibits the growth of SNU-16 human gastric cancer cells (IC50 = 12.4 µM) and increases apoptosis when used at a concentration of 50 µM. Amarogentin dose-dependently reduces tumor growth in a SNU-16 nude mouse xenograft model. Amarogentin may offer therapeutic potential for preventing or treating thromboembolic disorders, it prevents platelet activation through the inhibition of PLC γ2-PKC cascade and MAPK pathway.
More details are to be found on
supplier website
